The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.
Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback